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MinireviewA Novel Cytidine Deaminase
Affects Antibody Diversity
Ie-Ce germline transcripts are then spliced to combine
Im with Cm, and Ie with Ce, respectively. The role of the
germline transcripts is not known. It is postulated that a
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switch-specific endonuclease then cleaves the double-Chicago, Illinois 60637
strand DNA at random sites within or near Sm and the
downstream S region involved in the particular switch.
As the switch region repeats are varied, the endonucle-Antibody molecules are encoded by immunoglobulin (Ig)
ase(s) would not recognize a particular sequence butgenes and are produced exclusively in B lymphocytes.
rather a particular structure. Other mechanisms for pro-Site-specific recombination events (V(D)J recombina-
ducing the double-strand breaks are also possible, astion) occurring in precursor cells (preB) lead to the ex-
nothing is known about the process.pression in each B cell of a single heavy chain and a
Somatic Hypermutationsingle light chain gene, each with a specific variable (V)
The somatic hypermutation process also takes place inregion. An initial repertoire of millions of different B cells,
germinal centers in lymph nodes and spleen and, aseach with a different antigen binding site, is generated
discussed above, is also initiated when a B cell encoun-from about 100 V genes, their combinatorial joining with
ters an antigen that can react with its specific Ig mole-a small set of different J (and D) genes, and small dele-
cules. SHM is coupled with a very high rate of B celltions and insertions of nucleotides at the V(D)J joining
divisions (about once every 6 hr). As the mutation pro-sites. The Ig genes created by V(D)J recombination are
cess continues for about ten or more cell generations,further diversified by two processes; class switch re-
it generates a clone of related B cells expressing a vari-combination (CSR) alters the constant region and so-
ety of differently modified derivatives of the Ig heavymatic hypermutation (SHM) alters the variable region.
and light chain variable genes expressed by the founderWhen a mature B cell encounters an antigen that can
cell. B cells that produce mutated Igs with a high affinitybind to the Ig molecules expressed on its surface, both
for the immunizing antigen are selected for survival andof these processes are induced. Two papers in this issue
can become long lived memory cells.of Cell report a significant step in understanding the
SHM is limited to the variable region of the Ig genemechanisms involved in generating antibody diversity,
and its proximate flanks, covering a mutable stretch ofby showing that a novel cytidine deaminase (AID) plays
1 to 2 kb from the 59 end of the transcribed regiona crucial role in both CSR and SHM (Muramatsu et al.,
(Figure 2) (reviewed in Storb, 1996). SHM results in point2000; Revy et al., 2000).
mutations at a frequency of up to 20% of the nucleotidesClass Switch Recombination
within this region of the Ig gene. There is clear evidenceClass switch recombination and SHM both take place
that SHM is linked to transcription (Storb et al., 1998a).in lymphoid germinal centers, but not necessarily in the
Placing an Ig promoter 59 of the constant region of ansame cell at the same time. The germinal centers repre-
Ig gene causes mutation of the normally unmutated con-sent organized assemblies of B cells, as well as T cells
stant region (Peters and Storb, 1996). Removal of theand dendritic cells (Liu et al., 1991a). CSR alters the
Ig enhancers inhibits SHM (Betz et al., 1994). The mecha-constant (C) region of the heavy chain gene by switching
nism of creating the mutations is not understood, but itfrom the original Cm to one of five or six other C regions
is proposed that a mutator factor is delivered to the(in the mouse, these are in 59 to 39 order in the heavy
mutable target during transcription and, in collaborationchain locus, Cg3, g1, g2b, g2a, e, and a, and in man they
with certain DNA polymerases, induces somatic point
are g3, g1, a1, g2, g4, e, and a2). Switch recombination
mutations, rare deletions and insertions (Figure 3). DNA
results in the deletion of DNA sequences located in the
mismatch repair appears to correct certain mutations,
germline between the “switch” (S) region upstream of especially those derived from G or C nucleotides.
Cm, and one of the S regions located upstream of each Activation-Induced Cytidine Deaminase (AID)
of the downstream constant region genes (Figure 1). Germinal center B cells, the cells in which CSR and SHM
Each S region is composed of tandem short repetitive are active, produce a novel cytidine deaminase (AID)
sequences that are similar, but not identical to each that is expressed only in these cells (Muramatsu et al.,
other. 1999). Its expression is induced when mature B cells
The molecular basis of class switch recombination is are activated to undergo CSR and/or SHM. Its sequence
not understood (Stavnezer, 1996). The choice of the is homologous to the mammalian RNA editing deami-
downstream switch region is determined by cytokines; nase, APOBEC-1, which changes a single ribo-cytidine
for example, IL4 induces switching to Ce. The direct to uridine in the intestinal apolipoprotein-B mRNA. The
effect of cytokine action appears to be transcriptional amino acid homology of mouse AID with the mouse
activation of a promoter (named I region promoter) lo- catalytic APOBEC-1 subunit is 34%. AID has deaminase
cated upstream of each switch region and production activity when tested for deamination of deoxycytidine.
of germline transcripts that extend from the I region The homology of mouse AID with the mouse or human
through the associated C region (Figure 1). Im-Cm and editing APOBEC-1 is greater than that with general
mouse or human cytidine deaminases, or with human
CMP deaminase. It appears therefore that AID may be* To whom correspondence should be addressed (e-mail: stor@
midway.uchicago.edu). another RNA editing deaminase. Unlike APOBEC-1, it
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Figure 2. Distribution of Mutations in Somatic Hypermutation of Ig
Genes
are enlarged, indicating that the initiation of B cell activa-
tion is taking place and is actually enhanced.
The absence of CSR in AID-deficient mice is further
supported by the absence of switched Ig genes in acti-
vated B cells. Normally, after CSR, transcripts initiating
at the Im promoter and terminating 39 of the switched-
in C region are found in splenic B cells (Figure 1). In
AID-deficient mice no Im-Cg, Im-Ce, or Im-Ca transcripts
are found. However, most interestingly, germline tran-
scripts of the I-C type (e.g., Im-Cm, Ie-Ce) are found for
all constant regions when the B cells are stimulated
with the appropriate cytokines. This indicates that the
activation of the downstream switch acceptors does not
require AID. Thus, the initiation of CSR is normal, but
the final switch recombination does not take place in
CSR-deficient mice.
Surprisingly, somatic hypermutation of Ig genes also
appears to be severely diminished in AID-deficient mice.
The levels of SHM in IgM antibody–producing B cells is
reduced 10-fold to about 1/103 nucleotides. The analysis
was done with the use of LA-Taq polymerase, which
results in an error frequency of ,1/104 nucleotides in
the 30 PCR cycles used. Thus, while some mutations
were probably due to PCR errors, there could also be
true SHM changes. Thus, SHM in mouse is enhanced
by AID, but may not strictly require it. Perhaps additional
studies with hyperimmunized mice and using a DNA
polymerase, such as PFU, that creates even fewer errors
will show that AID is essential.
The human AID gene has now also been sequenced
Figure 1. Ig Gene Class Switch Recombination
(Muto et al., 2000). It maps to chromosome 12p13, a
Example of switching from Cm to Ce. S, switch region; the flags
region that a study by Durandy and collaborators (Revyindicate transcription promoters.
et al., 2000) implicates in the autosomal recessive form
of Hyper-IgM syndrome (HIGM2). HIGM2 is distinct from
does not bind to AU-rich RNA, nor does it deaminate HIGM1, which is caused by defects in the X-linked
apolipoprotein-B mRNA, although this is not surprising CD40L gene. HIGM2 manifests itself by defective CSR,
since the APOBEC-1 deaminase activity is highly se- defective SHM, and hyperplastic lymphoid germinal
quence specific. Therefore, a suitable substrate to test centers. In a tour-de-force, Revy et al. identified AID as
AID deaminase activity may not be available until the a candidate for HIGM2 in a genetic screen and charac-
putative target has been found. terized the molecular defect in the AID gene in 18 pa-
Interestingly, results reported in this issue of Cell show tients with HIGM2 from 12 families. Most of the patients
that AID is required for CSR and high levels of SHM had homozygous point mutations or deletions in one of
(Muramatsu et al., 2000; Revy et al., 2000). Overexpres- three of the five coding exons of AID, leading to mis-
sion of AID, in combination with switch-inducing cyto- sense mutations or stop codons. Some patients had a
kines, enhances CSR several fold in a switch-competent point mutation in one allele of the AID gene, and a dele-
B cell line (Muramatsu et al., 2000). Homozygous disrup- tion in the other. Most of the patients had no detectable
tion of the AID gene in mice completely eliminates CSR. IgG or IgA levels, strongly indicating that AID is essential
The mice have normal B cell development, so V(D)J for CSR. Eight patients produced some IgG and two of
recombination does not require AID. They respond to these also produced IgA, but at levels at least ten times
immunization with specific antibody production, but the lower than age-matched controls. These may be ex-
antibodies are all of the IgM class, whereas normally plained by residual AID activity in certain missense mu-
tations, or a few persisting maternal B cells.other Ig classes predominate. Their germinal centers
Minireview
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deaminase. As AID expression is restricted to germinal
centers and CSR and SHM both require AID, at least in
humans, it is likely that AID has very specific targets for
its action. This high degree of specificity resembles that
of APOBEC1, which seems to have one unique ribo-
cytidine target in the APO-B mRNA.
The initial events in CSR, up to the production of
spliced germline I-C transcripts in the m, and g, e, or a
loci, are normal in AID-deficient mice. Thus, the require-
ment for AID must be in the postulated subsequent dou-
ble-strand break and break repair to join Sm with one
of the downstream S regions. Clearly, CSR requires dou-
ble-strand break repair by nonhomologous end joining
as evidenced by the requirement for Ku70, Ku80, and
the DNA-dependent protein kinase, SCID (Rolink et al.,
1996; Casellas et al., 1998; Manis et al., 1998). These
three proteins are also required for V(D)J recombination,
but this process is normal in AID-deficient mice and
humans. Thus, it is likely that a CSR-specific component
of double-strand break repair, or of a process preceding
the repair, is the target for AID. It is possible that AID
acts as a DNA deaminase directly on the switch region
DNA, but there is no precedent for such an activity.
There is also no cogent model of how deamination of
one or more C residues in the germline I-C RNAs would
aid CSR. Thus, at this time there is no strong basis for
suggesting that AID acts directly on the DNAs and RNAs
involved in CSR. However, perhaps the most likely step
for AID action in CSR is in the creation of the double-
strand breaks in the Sm and downstream S region DNA
sequences. AID may be required for modification by
cytidine deamination of the mRNAs encoding one or
Figure 3. Model of Somatic Hypermutation of Ig Genes more of the enzymes involved in the process. The
E, Ig enhancer; IEB, Ig enhancer binding proteins; MuF, mutator mRNAs for CSR-specific nuclease(s) are logical targets
factor; pol, RNA polymerase; Fen1, flap endonuclease 1; x, mutation. for AID. The deaminase specificity of APOBEC-1 is de-
termined by a cofactor, ACF (Mehta et al., 2000). Like-
wise, AID, which contains the catalytic site for deamina-Somatic hypermutation was also investigated in ex-
tion, may require a cofactor that is specific for editingpressed IgM genes in peripheral blood of five of the
the mRNA of the nuclease(s) responsible for the breakspatients. Two had no mutations, compared with 2.6%
in CSR. One would postulate then, that the combinationto 6.3% of nucleotides mutated in the variable region
of AID and its cofactor would cause deamination of onein control subjects. Three had significant, albeit low,
or more C residues in the CSR nuclease mRNA(s) andlevels of SHM. Two of these also showed some CSR,
that this editing would be required for the productionsuggesting perhaps residual AID activity as noted
of the active nuclease(s). In analogy to the editing ofabove.
Apo-B by APOBEC-1, a single nuclease mRNA couldHIGM2 patients show an extreme lymphoid hyperpla-
give rise to two different nucleases by RNA editing viasia, due to greatly enlarged germinal centers (Revy et
AID. Finally, the breaks would be repaired by the generalal., 2000). It is not clear why in AID-deficient humans
nonhomologous end-joining machinery.and mice germinal centers are hyperplastic, although
AID is the first gene that has been found to be requiredRevy et al. suggest that the hyperproliferation of germi-
for SHM in man. In mouse, AID may not be absolutelynal center founder B cells is not controlled when somatic
required, but it clearly enhances SHM. SHM can behypermutation does not take place. How such a feed-
divided into three stages, cellular activation accompa-back inhibition would proceed is unknown. But, if this
nied by germinal center formation, mutation, and selec-model is correct, it may imply that, normally, mutating
tion of B cells producing mutated, functional, and oftenB cells are frequently checked, perhaps by interaction
high-affinity antibodies. The first stage appears to bewith follicular dendritic cells (Liu et al., 1991b), that this
normal in AID-deficient mice and humans. Germinal cen-check perhaps involves a slowing or stop of prolifera-
ters are formed and in fact, germinal centers are en-tion, and that normally only a subset of cells reenter the
larged due to increased numbers of activated B cells.cell cycle and continue to undergo SHM.
The selection stage may be defective in AID deficiency,What Is the Role of AID in CSR and SHM?
although selection seems not required in mutating BIt has not been determined whether AID normally acts
cells in cell culture which persist in the absence of aas a DNA or RNA deaminase. In vitro, deamination of
selection process. In vivo, positive selection appears tomonomeric deoxycytidine was efficient (Muramatsu et
be required. Mutating B cells are predestined to dieal., 1999). On the other hand, since AID has the highest
homology with APOBEC1, it is likely an RNA editing by apoptosis, unless selected (Liu et al., 1991b). Thus,
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Catalan, N., Forveille, M., Dufourcq-Lagelouse, R., Gennery, A., Tez-between the mutator factor, exonuclease, and one or
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It is unlikely that AID directly introduces mutations
Storb, U. (1996). Curr. Op. Immunol. 8, 206–214.into the Ig DNA, as there is no target specificity for SHM.
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despite certain preferences for short hot spots of SHM.
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The most likely targets for AID would be any of the DNA T.E. (1998b). J. Exp. Med. 188, 689–698.
enzymes proposed to be involved in SHM (Figure 3). By
analogy to the proposed role of AID as required for Note Added in Proof
activation of endonuclease(s) in CSR, AID may be in-
volved in activating the proposed SHM mutator factor A recent publication puts a new spin on the possible role of AID in
CSR (and perhaps also SHM) (Tian and Alt, 2000). Germline tran-endonuclease gene, or more likely its mRNA, by deami-
scription is known to be essential for CSR. In vitro, S region tran-nating one or more cytidines. The unedited mRNA would
scripts have been found to result in R loops with the S DNA (Reabanencode a protein with no or, in mouse, only low SHM
et al., 1994; Daniels and Lieber, 1995). Tian and Alt (2000) now report
activity. that in vitro, such R loops can be cleaved by certain endonucleases.
One of the HIGM2 patients (P18) showed a respect- This raises the interesting possibility that a general nuclease could
be made specific for S region R loops by the action of AID.able level of SHM, with six of nine sequences containing
mutations and an overall mutation frequency of 0.9%,
Referenceswhile no CSR could be detected (Revy et al., 2000). This
finding suggests that the mechanisms of AID function
Daniels, G., and Lieber, M. (1995). Nucleic Acids Res. 23, 5006–5011.
in CSR and SHM may not be the same. (Alternatively, in
Reaban, M., Lebowitz, J., and Griffin. (1994). J. Biol. Chem. 269,
man as apparently in mouse, AID-induced modification 21850–21857.
may not be essential for SHM, only for high levels of Tian, M., and Alt, F. (2000). J. Biol. Chem. 257, 24163–24172.
SHM. Other patients with the same mutation will have
to be tested for this CSR/SHM dichotomy.) It would be
most interesting to express the mutated AID gene of
patient P18 in AID-deficient B cells or mice to determine
whether AID acts differently in CSR and SHM. AID may
have deaminase activity for different mRNAs or may
associate with different specificity-determining cofac-
tors in CSR and SHM. As the details of CSR and SHM
are not known, several other models are possible for
AID involvement in these processes. Further under-
standing of the AID function will no doubt play a signifi-
cant role in the final unraveling of the generation of
antibody diversity.
